## Antimicrobial Utilisation Surveillance in Australian Hospitals

## Victoria

## Statewide benchmarking report – Emergency Department July 2023 – December 2023

Antibacterial utilisation rates provided in this report are calculated using the number of defined daily doses (DDDs) of the antibacterial class consumed each month per 1,000 Emergency Department presentations.

Contributing hospitals are assigned according to Australian Institute for health and Welfare (AIHW) defined peer groups.<sup>1</sup> Deidentified contributor codes can be located via the 'Maintain My Hospital' drop-down menu in the NAUSP Portal.


DDD values for each antimicrobial are assigned by the World Health Organization based on the "assumed average maintenance dose per day for the main indication in adults". DDDs are reviewed annually by the WHO as dosing recommendations change over time. For more information refer to: <a href="https://www.whocc.no/atc\_ddd\_methodology/purpose\_of\_the\_atc\_ddd\_system/">https://www.whocc.no/atc\_ddd\_methodology/purpose\_of\_the\_atc\_ddd\_system/</a>

The chart below presents aggregated antibacterial usage data in the Emergency Department for the respective contributing hospitals over the six-month period from 1 July 2023 to 31 December 2023. [Note: Not all NAUSP contributors are able to provide stratified data for the Emergency Department].

\_

<sup>&</sup>lt;sup>1</sup> AIHW. *Hospital resources 2017-18*: *Australian hospital statistics*. Available from https://www.aihw.gov.au/reports/hospitals/hospital-resources-2017-18-ahs/data

Chart 1: Emergency Department antibacterial usage rates (DDD/1000 emergency presentations) in NAUSP contributor hospitals, by peer group, Victoria, July-December 2023



[Alimentary antibiotics = rifaximin, fidaxomicin, paromomycin. Other = amphenicols, antimycotics, combinations for eradication of Helicobacter pylori, monobactams, nitrofurans, linezolid, daptomycin, other cephalosporins, polymyxins, rifamycins, second-generation cephalosporins, steroids, streptogramins and streptomycin.

## This report includes data from the following 28 hospitals in VIC:

Albury Wodonga - Albury Albury Wodonga - Wodonga

Alfred Hospital Angliss Hospital Austin Hospital

**Ballarat Base Hospital** 

Bendigo Health Box Hill Hospital

Central Gippsland Health

Frankston Hospital Geelong Hospital

Grampians Health - Horsham Holmesglen Private Hospital John Fawkner Private Hospital Maroondah Hospital
Mercy Women's Hospital

Rosebud Hospital

Royal Melbourne Hospital Sandringham Hospital St John Of God Geelong

St Vincent's Hospital Melbourne

Swan Hill District Health The Northern Hospital

Warrnambool Base Hospital Werribee Mercy Hospital West Gippsland Hospital Western Health Footscray Western Health Sunshine

Disclaimer: Data presented in this report were correct at the time of publication. As additional hospitals join NAUSP, retrospective data are included. Data may change when quality assurance processes identify the need for data updates.

The National Antimicrobial Utilisation Surveillance Program (NAUSP) is funded by the Commonwealth Department of Health and Aged Care (DOHAC). NAUSP is administered by Antimicrobial Programs, Communicable Disease Control Branch, Department for Health and Wellbeing, Government of South Australia. All individual hospital data contributed to this program will remain de-identified unless otherwise agreed in writing. Aggregated data may be provided to all contributors, the ACSQHC and DOHAC.

	fidovomioin		alindamyain
Alimentary antibiotics	fidaxomicin	Lincosamides	clindamycin
	paromomycin rifaximin		lincomycin azithromycin
Aminoglycosides	amikacin		clarithromycin
		Macrolides	•
	gentamycin		erythromycin
	neomycin		roxithromycin
	tobramycin		spiramycin
ß-lactamase inhibitor combinations	amoxicillin - clavulanate	Monobactams	aztreonam
	piperacillin - tazobactam	Nitrofuran derivatives	nitrofurantoin
ß-lactamase resistant penicillins	dicloxacillin	Polymyxins	colistin
	flucloxacillin		polymyxin B
ß-lactamase sensitive penicillins	benzathine benzylpenicillin	Second-generation cephalosporins	cefaclor
	benzylpenicillin		cefamandole
	phenoxymethylpenicillin		cefotetan
	procaine benzylpenicillin		cefoxitin
Carbapenems	doripenem		cefuroxime
	ertapenem	Steroid antibacterials	fusidic acid
	imipenem - cilastatin	Streptogramins	pristinamycin
	meropenem	Streptomycins	streptomycin
	meropenem - vaborbactam	Sulfonamide- trimethoprim combinations	sulfamethoxazole - trimethoprim
Extended-spectrum penicillins	amoxicillin	Tetracyclines	doxycycline
	ampicillin		minocycline
	pivmecillinam		tetracycline
	temocillin		tigecycline
First-generation cephalosporins	cefalexin	Third-generation cephalosporins	cefixime
	cefalotin		cefotaxime
	cefazolin		ceftazidime
Fluoroquinolones	ciprofloxacin		ceftazidime - avibactam
	levofloxacin		ceftriaxone
	moxifloxacin	Trimethoprim	trimethoprim
	norfloxacin	•	ceftaroline fosamil
Fourth-generation cephalosporins	cefepime		ceftolozane - tazobactam
	cefpirome	Oth on the story	daptomycin
Glycopeptides	dalbavancin	Other (including other cephalosporins and penems)	faropenem
	oritavancin		fosfomycin
	teicoplanin		linezolid
	vancomycin		rifampicin
Imidazole derivatives	metronidazole		tedizolid
Intermediate-acting sulfonamides	sulfadiazine		